Ladenburg Thalmann Initiates Coverage On Sonnet BioTherapeutics with Buy Rating, Announces Price Target of $7
Portfolio Pulse from Benzinga Newsdesk
Ladenburg Thalmann analyst Ahu Demir has initiated coverage on Sonnet BioTherapeutics (NASDAQ:SONN) with a Buy rating and set a price target of $7.

November 27, 2023 | 2:00 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Ladenburg Thalmann has initiated coverage on Sonnet BioTherapeutics with a Buy rating and a price target of $7.
Initiation of coverage by an analyst with a Buy rating typically indicates a positive outlook on the stock, which can lead to increased investor interest and potentially a rise in stock price in the short term. The price target of $7 suggests significant upside potential from current levels.
CONFIDENCE 90
IMPORTANCE 90
RELEVANCE 100